Armata Pharmaceuticals (ARMP) Net Cash Flow (2013 - 2026)
Armata Pharmaceuticals (ARMP) posted Net Cash Flow of -$5.2 million for Q1 2026, up 14.24% sequentially from -$6.1 million in Q4 2025, and down 325.57% YoY from $2.3 million in Q1 2025.
Armata Pharmaceuticals (ARMP) Net Cash Flow (2013 - 2026) Analysis & Trends
Armata Pharmaceuticals has reported Net Cash Flow for 14 years, with the latest figure at -$5.2 million in Q1 2026.
- Quarterly Net Cash Flow fell 325.57% year-over-year to -$5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.2 million (up 68.76% YoY) and the FY2025 annual result came in at -$693000.0, up 84.5% from the prior year.
- Net Cash Flow rose to -$5.2 million in Q1 2026 per ARMP's latest filing, from -$6.1 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $40.9 million in Q1 2022 and troughed at -$12.6 million in Q2 2023.
- A 5-year average of -$153764.7 and a median of -$7.4 million in 2025 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 219.23% in 2022, down 488.93% in 2022.
- Over 5 years, Net Cash Flow stood at -$10.5 million in 2022, then retreated by 0.09% to -$10.5 million in 2023, then increased by 25.51% to -$7.8 million in 2024, then advanced by 22.7% to -$6.1 million in 2025, then grew by 14.24% to -$5.2 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$5.2 million, -$6.1 million, and $10.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Armata Pharmaceuticals | 182.82 Mn | 158.82 Mn | - | 19.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.20 Mn |
| Jun 30, 2026 | 19.20 Mn |
| Mar 31, 2026 | -5.20 Mn |
| Mar 31, 2026 | -5.20 Mn |
| Dec 31, 2025 | -6.07 Mn |
| Dec 31, 2025 | -6.07 Mn |
| Sep 30, 2025 | 10.43 Mn |
| Sep 30, 2025 | 10.43 Mn |
| Jun 30, 2025 | -7.36 Mn |
| Jun 30, 2025 | -7.36 Mn |
| Mar 31, 2025 | 2.31 Mn |
| Mar 31, 2025 | 2.31 Mn |
| Dec 31, 2024 | -7.85 Mn |
| Dec 31, 2024 | -7.85 Mn |
| Sep 30, 2024 | -9.26 Mn |
| Sep 30, 2024 | -9.26 Mn |
| Jun 30, 2024 | -11.46 Mn |
| Jun 30, 2024 | -11.46 Mn |
| Mar 31, 2024 | 24.10 Mn |
| Mar 31, 2024 | 24.10 Mn |